See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Sweet Freedom™ No Sugar Added Desserts

Mike Cecil and John Kennedy

Sweet Freedom™ No Sugar Added Desserts

Insulin Inhalation Prototype Demo

J. Scott MacGregor

Insulin Inhalation Prototype Demo

Diabetes Health and CVS Pharmacy

Special Coupon Savings Magazine

Diabetes Health and CVS Pharmacy

Novo Nordisk Archives

Novo Nordisk

Page 5
FDA Hedges Approval of Long-Acting Byetta, Asks Amylin for More Information

The U.S. Food and Drug Administration has withheld approval of Bydureon, the once-weekly version of the popular type 2 diabetes drug Byetta.  The agency has asked its manufacturer, Amylin, for more information regarding Bydureon's manufacture, labeling, and risk management plan. It did not, however, request further information on tests of the drug itself-an indication that the agency probably intends to grant marketing permission once it has dotted all the i's and crossed all the t's involved in the approval process.

Comments 0 comments - Mar 29, 2010 - * * * * *

Starting Treatment Early Doubles Chance of Success for People with Diabetes

The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.

Comments 2 comments - Mar 12, 2010 - * * * * *

Amylin Hopes to Begin U.S. Sales of Long-Acting Byetta Early This Year

Amylin Pharmaceuticals has announced that it expects to begin selling a once-weekly version of its diabetes drug, Byetta, by the end of the year. The company reports that the FDA is nearing final inspections of its manufacturing plant and could give the go-ahead for U.S. sales in early March.

Comments 2 comments - Mar 4, 2010 - * * * * *

FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.

Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.

Comments 5 comments - Feb 27, 2010 - * * * * *

Diabetes and Pre-Diabetes Cost the U.S. $218 Billion in 2007: En Route to $336 Billion by 2034

A study commissioned by healthcare company Novo Nordisk has reported that the cost of diabetes and pre-diabetes to the U.S. economy in 2007 was $218 billion. The study, conducted by The Lewin Group, projected that by 2034, the two conditions will cost the economy $336 billion per year.

Comments 1 comment - Feb 3, 2010 - * * * * *

Novo, Upping the Ante in the Race for an Oral GLP-1 Drug, Tests a Pill Version of Victoza

Denmark-based Novo Nordisk has begun a Phase 1 trial of a pill form of a GLP-1 drug very similar to its Victoza product. The trial will involve  155 British patients with type 2 diabetes. The test on human subjects, although very early-stage,  puts the company in the lead to develop an oral form of a GLP-1 drug.

Comments 0 comments - Feb 1, 2010 - * * * * *

Novo Nordisk's Victoza Receives FDA Approval for the Treatment of Type 2 Diabetes

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

Comments 4 comments - Jan 28, 2010 - * * * * *

Novo Enters Phase 1 Test of an Insulin Pill

Denmark-based Novo Nordisk A/S has begun phase 1 testing of an insulin pill that, if successful, could replace injections as the primary means of blood sugar control for millions of people with type 1 and type 2 diabetes. The company has enrolled 80 volunteer German test subjects in the study and expects to have preliminary results by the first half of 2011. The test group consists of both people with diabetes and people without it.

Comments 12 comments - Dec 24, 2009 - * * * * *

Diabetes Population to Double and Diabetes Costs to Nearly Triple in 25 Years, New Study Shows

PRINCETON, NJ (November 27, 2009) - The diabetes population in the United States will almost double over the next 25 years and annual medical spending on the disease is projected to hit $336 billion, up from $113 billion today, according to a study published in the December issue of Diabetes Care.  The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis by a team from the University of Chicago.

Comments 5 comments - Nov 27, 2009 - * * * * *

Primary Care Doctors, Endocrinologists Feel Ill-Equipped to Provide Ideal, Multi-Disciplinary Team Care

PRINCETON, N.J., Nov. 19 /PRNewswire/ -- Nearly one-third of doctors surveyed said they did not have enough time and did not receive sufficient reimbursement to provide comprehensive care to their patients with diabetes, according to the results of a study of endocrinologists and primary care doctors published in American Health & Drug Benefits.

Comments 4 comments - Nov 20, 2009 - * * * * *

Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.